Abstract
The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
Keywords: EGFR, HER2, mIRs, Cancer Stem Cells, Drug Resistance, Metastasis.
Current Pharmaceutical Design
Title:Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Volume: 22 Issue: 16
Author(s): Dariusz Rakus, James A. McCubrey, Stephen L. Abrams, Zoya Demidenko, Agustino Tafuri, Michelle Milella, Melchiorre Cervello, Giuseppe Montalto, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Joerg Basecke, Joanna Dulinska-Litewka, Piotr Laidler, Agnieszka Gizak, Linda S. Steelman, Lyudmyla Drobot, Concettina Fenga, Aurora Scalisi, Ferdinando Nicoletti, Saverio Candido, Massimo Libra, Sandra Marmiroli, Luca M. Neri, Alberto M. Martelli, Matilde Y. Follo, Lucio Cocco, Kvin Lertpiriyapong and Timothy Fitzgerald
Affiliation:
Keywords: EGFR, HER2, mIRs, Cancer Stem Cells, Drug Resistance, Metastasis.
Abstract: The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
Export Options
About this article
Cite this article as:
Rakus Dariusz, McCubrey A. James, Abrams L. Stephen, Demidenko Zoya, Tafuri Agustino, Milella Michelle, Cervello Melchiorre, Montalto Giuseppe, Maksimovic-Ivanic Danijela, Mijatovic Sanja, Basecke Joerg, Dulinska-Litewka Joanna, Laidler Piotr, Gizak Agnieszka, Steelman S. Linda, Drobot Lyudmyla, Fenga Concettina, Scalisi Aurora, Nicoletti Ferdinando, Candido Saverio, Libra Massimo, Marmiroli Sandra, Neri M. Luca, Martelli M. Alberto, Follo Y. Matilde, Cocco Lucio, Lertpiriyapong Kvin and Fitzgerald Timothy, Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160304151011
DOI https://dx.doi.org/10.2174/1381612822666160304151011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Drug Targets The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Novel Strategies of Regenerative Medicine Using Chemical Compounds
Current Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry Editorial (Thematic Issue: Contemporary siRNA Therapeutics and the Current State-of-Art)
Current Pharmaceutical Design Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Metal Complexes of Uracil Derivatives with Cytotoxicity and Superoxide Scavenging Activity
Letters in Drug Design & Discovery Id-1B, an Alternatively Spliced Isoform of the Inhibitor of Differentiation-1, Impairs Cancer Cell Malignancy Through Inhibition of Proliferation and Angiogenesis
Current Molecular Medicine Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
Current Cancer Drug Targets